This company is no longer active
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Humanigen Toekomstige groei
Future criteriumcontroles 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Humanigen.
Belangrijke informatie
n/a
Groei van de winst
n/a
Groei van de winst per aandeel
Biotechs winstgroei | 28.6% |
Inkomstengroei | n/a |
Toekomstig rendement op eigen vermogen | n/a |
Dekking van analisten | None |
Laatst bijgewerkt | n/a |
Recente toekomstige groei-updates
Recent updates
Humanigen GAAP EPS of -$0.43 misses by $0.11, revenue of $1.04M beats by $0.69M
Aug 12Humanigen plunges 57% as trial for COVID-19 therapy fails
Jul 13Humanigen jumps over 10% after peer-reviewed data on COVID-19 therapy
Jul 06Humanigen (NASDAQ:HGEN) Has Debt But No Earnings; Should You Worry?
Oct 30Health Check: How Prudently Does Humanigen (NASDAQ:HGEN) Use Debt?
Jul 14Humanigen begins rolling submission for lenzilumab in COVID-19 in U.K.
Jun 14Humanigen submits lenzilumab COVID-19 EUA application to FDA
May 28Humanigen is on the rise after publication of Phase 3 data for COVID-19 therapy
May 05Humanigen, Inc.'s (NASDAQ:HGEN) Intrinsic Value Is Potentially 61% Above Its Share Price
May 05We Might See A Profit From Humanigen, Inc. (NASDAQ:HGEN) Soon
Mar 31Is Humanigen, Inc. (NASDAQ:HGEN) Popular Amongst Institutions?
Feb 26Enrollment completed in Humanigen's late-stage study of lenzilumab in COVID-19
Jan 29Humanigen partners with EVERSANA for launch and commercialization of Lenzilumab for COVID-19 treatment
Jan 11We Think Humanigen (NASDAQ:HGEN) Can Afford To Drive Business Growth
Jan 04Humanigen secures new U.S. patent for lenzilumab
Dec 28Enrollment completed in Humanigen's early-stage ifabotuzumab study in glioblastoma multiforme
Dec 17Humanigen EPS misses by $0.16
Nov 11Humanigen up 7% on partnership with U.S. government to advance lenzilumab for COVID-19
Nov 06Humanigen executes lenzilumab licensing deal in Asia for COVID-19
Nov 03Humanigen Dosing Phase 3 Covid Patients, And Other News: The Good, Bad And Ugly Of Biopharma
Nov 01Dosing underway in lenzilumab late-stage study in COVID-19
Oct 30Dosing underway in mid-stage study of Humanigen's lenzilumab in COVID-19
Oct 29In dit gedeelte presenteren we gewoonlijk prognoses voor de omzet- en winstgroei op basis van de consensusramingen van professionele analisten om beleggers te helpen begrijpen in hoeverre het bedrijf in staat is winst te genereren. Maar omdat Humanigen onvoldoende gegevens uit het verleden heeft verstrekt en geen analistenprognose heeft, kan de toekomstige winst niet betrouwbaar worden berekend door gegevens uit het verleden te extrapoleren of analistenprognoses te gebruiken.
Dit is een vrij zeldzame situatie, aangezien 97% van de bedrijven die worden gedekt door SimplyWall St wel financiële gegevens uit het verleden hebben.
Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
3/31/2023 | 2 | -54 | -64 | -64 | N/A |
12/31/2022 | 3 | -71 | -77 | -77 | N/A |
9/30/2022 | 3 | -109 | -94 | -94 | N/A |
6/30/2022 | 4 | -152 | -125 | -125 | N/A |
3/31/2022 | 4 | -192 | -168 | -168 | N/A |
12/31/2021 | 4 | -237 | -184 | -184 | N/A |
9/30/2021 | 3 | -235 | -175 | -175 | N/A |
6/30/2021 | 2 | -199 | -151 | -151 | N/A |
3/31/2021 | 1 | -153 | -105 | -105 | N/A |
12/31/2020 | 0 | -90 | -70 | -70 | N/A |
9/30/2020 | N/A | -59 | -47 | -47 | N/A |
6/30/2020 | N/A | -31 | -24 | -24 | N/A |
3/31/2020 | N/A | -10 | -4 | -4 | N/A |
12/31/2019 | N/A | -10 | -4 | -4 | N/A |
9/30/2019 | N/A | -10 | -5 | -5 | N/A |
6/30/2019 | N/A | -10 | -5 | -5 | N/A |
3/31/2019 | N/A | -9 | -5 | -5 | N/A |
12/31/2018 | N/A | -12 | -6 | -6 | N/A |
9/30/2018 | N/A | -13 | -7 | -7 | N/A |
6/30/2018 | N/A | -18 | -10 | -10 | N/A |
3/31/2018 | N/A | -22 | -12 | -12 | N/A |
12/31/2017 | N/A | -22 | -14 | -14 | N/A |
9/30/2017 | N/A | -24 | -15 | -15 | N/A |
6/30/2017 | N/A | -21 | -20 | -20 | N/A |
3/31/2017 | N/A | -27 | -23 | -23 | N/A |
12/31/2016 | N/A | -27 | N/A | -21 | N/A |
9/30/2016 | N/A | -35 | N/A | -26 | N/A |
6/30/2016 | N/A | -37 | N/A | -23 | N/A |
3/31/2016 | N/A | -31 | N/A | -22 | N/A |
12/31/2015 | N/A | -35 | N/A | -29 | N/A |
9/30/2015 | N/A | -32 | N/A | -28 | N/A |
6/30/2015 | N/A | -33 | N/A | -30 | N/A |
3/31/2015 | N/A | -37 | N/A | -34 | N/A |
12/31/2014 | N/A | -38 | N/A | -36 | N/A |
9/30/2014 | 0 | -39 | N/A | -39 | N/A |
6/30/2014 | 0 | -42 | N/A | -39 | N/A |
3/31/2014 | 0 | -44 | N/A | -42 | N/A |
12/31/2013 | 0 | -42 | N/A | -39 | N/A |
9/30/2013 | 0 | -43 | N/A | -37 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: Insufficient data to determine if HGEN.Q's forecast earnings growth is above the savings rate (2.4%).
Winst versus markt: Insufficient data to determine if HGEN.Q's earnings are forecast to grow faster than the US market
Hoge groeiwinsten: Insufficient data to determine if HGEN.Q's earnings are expected to grow significantly over the next 3 years.
Omzet versus markt: Insufficient data to determine if HGEN.Q's revenue is forecast to grow faster than the US market.
Hoge groei-inkomsten: Insufficient data to determine if HGEN.Q's revenue is forecast to grow faster than 20% per year.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Insufficient data to determine if HGEN.Q's Return on Equity is forecast to be high in 3 years time